rs-130830 and Hypertrophy--Left-Ventricular

rs-130830 has been researched along with Hypertrophy--Left-Ventricular* in 1 studies

Other Studies

1 other study(ies) available for rs-130830 and Hypertrophy--Left-Ventricular

Article	Year
Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease. Journal of medicinal chemistry, 2010, Sep-23, Volume: 53, Issue:18 α-Sulfone-α-piperidine and α-tetrahydropyranyl hydroxamates were explored that are potent inhibitors of MMP's-2, -9, and -13 that spare MMP-1, with oral efficacy in inhibiting tumor growth in mice and left-ventricular hypertrophy in rats and in the bovine cartilage degradation ex vivo explant system. α-Piperidine 19v (SC-78080/SD-2590) was selected for development toward the initial indication of cancer, while α-piperidine and α-tetrahydropyranyl hydroxamates 19w (SC-77964) and 9i (SC-77774), respectively, were identified as backup compounds. Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Biological Availability; Cardiovascular Agents; Cartilage, Articular; Cattle; Crystallography, X-Ray; Humans; Hydroxamic Acids; Hypertrophy, Left Ventricular; Macaca fascicularis; Matrix Metalloproteinase Inhibitors; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Piperidines; Pyrans; Rats; Structure-Activity Relationship; Sulfones; Xenograft Model Antitumor Assays	2010

Article

Year

Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.

Journal of medicinal chemistry, 2010, Sep-23, Volume: 53, Issue:18

α-Sulfone-α-piperidine and α-tetrahydropyranyl hydroxamates were explored that are potent inhibitors of MMP's-2, -9, and -13 that spare MMP-1, with oral efficacy in inhibiting tumor growth in mice and left-ventricular hypertrophy in rats and in the bovine cartilage degradation ex vivo explant system. α-Piperidine 19v (SC-78080/SD-2590) was selected for development toward the initial indication of cancer, while α-piperidine and α-tetrahydropyranyl hydroxamates 19w (SC-77964) and 9i (SC-77774), respectively, were identified as backup compounds.

Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Biological Availability; Cardiovascular Agents; Cartilage, Articular; Cattle; Crystallography, X-Ray; Humans; Hydroxamic Acids; Hypertrophy, Left Ventricular; Macaca fascicularis; Matrix Metalloproteinase Inhibitors; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Piperidines; Pyrans; Rats; Structure-Activity Relationship; Sulfones; Xenograft Model Antitumor Assays

2010